Pain & Pyrexia

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Pain & Pyrexia Resource Center

Welcome to the MPR Pain & Pyrexia Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Higher Pain Tolerance for Athletes Than Active Controls

Athletes seem to have significantly higher pain tolerance than normally-active people.

Inadequate Pain Meds in ER for Patients With Long-Bone Fx

The majority of patients with long-bone fractures receive inadequate pain medication in the emergency department, and disparities in management exist.

Predictors of Length of Hospital Stay After Spine Surgery ID'd

A variety of pre-, intra-, and postoperative factors contribute to increased length of stay (LOS) for patients who undergo level 1 minimally invasive (MIS) transforaminal interbody fusions (TLIF) spine surgery.

Low Back Pain Improves Soon After Treatment, but Still Lingers

For patients with acute or persistent low back pain, pain and disability improve in the first six weeks of treatment, but low-to-moderate pain and disability tend to persist at one year.

Sumatriptan/Naproxen Helpful in Treating Teens' Migraines

Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents.

NUCYNTA ER

10/28/2011

Janssen Pharmaceuticals, Inc.

Pharmacological Class: Opioid.

Active Ingredient(s): Tapentadol 50mg, 100mg, 150mg, 200mg, 250mg; ext-rel tabs.

Indication: Moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Not for as-needed use.

LAZANDA

10/21/2011

Archimedes Pharma

Pharmacological Class: Opioid.

Active Ingredient(s): Fentanyl 100mcg, 400mcg; per 100mcL nasal spray.

Indication: Breakthrough pain, in opioid-tolerant patients already receiving and who are tolerant to continuous opioid therapy for underlying persistent cancer pain. Opioid-tolerant patients are those taking oral morphine ≥60mg/day, transdermal fentanyl ≥25mcg/hr, oral oxycodone ≥30mg/day, oral hydromorphone ≥8mg/day, oral oxymorphone ≥25mg/day, or equianalgesic dose of another opioid for ≥1 week.